Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06601166 · ClinicalTrials.gov registry record · NA
CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin
A NA study, sponsored by DexCom.
- Active
- Registry status
- NA
- Development phase
- 283
- Enrollment target
NCT06601166: Active NA study, sponsored by DexCom.
NCT06601166 is a NA study that is active but no longer recruiting, run by DexCom. The registered enrollment target is 283 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06601166, a NA study, is active but no longer recruiting, sponsored by DexCom.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 283 participants
- Enrollment target
Study Summary
This multi-center study is a 26-week randomized controlled trial (RCT) in which adults (≥18 years) with type 2 diabetes (T2D) not using insulin and managed in a primary-care setting will be randomly assigned 1:1 to either use of real-time continuous glucose monitoring (CGM) or routine care (RC) plus interval blinded CGM wear.
Primary Outcome
The primary outcome for the Primary RCT is HbA1c at 26 weeks adjusted for baseline (equivalent to change in HbA1c from baseline to 26 weeks).
Interventions
- DEVICE CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2026-12-16 |
| Phase | NA |
What the registry record for NCT06601166 still lists
NCT06601166 is an interventional study that assigns participants to a tested intervention. The registered 283 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which CGM is the first listed.
NCT06601166 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06601166 about?
NCT06601166 is a clinical study titled "CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin". This multi-center study is a 26-week randomized controlled trial (RCT) in which adults (≥18 years) with type 2 diabetes (T2D) not using insulin and managed in a primary-care setting will be randomly assigned 1:1 to either use of real-time continuous glucose monitoring (CGM) or routine care (RC) plus...
What is the current status of trial NCT06601166?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 283 participants. The study started on 2024-08-15. Estimated completion is 2026-12-16.
What interventions are being tested in trial NCT06601166?
The interventions under investigation include: CGM (DEVICE).
Who is sponsoring clinical trial NCT06601166?
This trial is sponsored by DexCom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06601166's enrollment target sits among peer trials
283 378th of 2000 higher than 1,622 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06856694 · 283 participants · NA
RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer
- NCT05263206 · 284 participants · Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- NCT05769218 · 284 participants · NA
PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
- NCT06856577 · 284 participants · Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI